KWKaren M. Wagner

Karen M. Wagner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karen M. Wagner has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pangenome Architecture and Accessory Gene-Driven Population Structure of Staphylococcus aureus Revealed by a Hospital-Adjacent Environmental Isolate

    by Wellington Francisco Rodrigues, Laise Mazurek, Renata Botelho Miguel, Geovana Pina Vilela, Amanda Bertinetti Tres, Sabrina Martins Calegari, Ferdinando Agostinho, Jamil Miguel-Neto, Melissa Carvalho Martins-De-Abreu, Karen M. Wagner, et al.

    Staphylococcus aureus is a globally distributed bacterium that spans interconnected human, animal, and environmental niches and is a major driver of antimicrobial resistance. Environmental and wildlife-associated isolates from hospital-surrounding settings remain underrepresented in comparative genomic studies. To address this gap, we integrated a newly sequenced environmental isolate recovered from pigeon fecal samples collected around a hospital into a standardized pangenome framework composed of 99 reproducibly selected RefSeq genomes plus the environmental isolate S_S3. Using uniform genome annotation and orthologous gene family clustering, we identified an open pangenome of 8366 gene families (Heaps’ law γ = 0.275), consistent with the high genomic plasticity previously reported for S. aureus. The core genome stabilized at approximately 1757 genes, including 1651 genes conserved across all genomes. Gene frequency spectra showed a dominant cloud genome and a structured shell fraction contributing to interstrain differentiation. Jaccard-based gene content similarity resolved clusters shaped mainly by accessory gene composition. The environmental isolate retained the complete core genome, carried only 15 isolate-specific gene families (0.18% of the pangenome), and clustered within an established lineage. Its unique content included a lincosamide resistance-associated locus and efeB, a gene potentially related to heme or iron metabolism and oxidative stress response. These findings highlight a conserved genomic backbone over a dynamic accessory reservoir and support One Health genomic surveillance that includes wildlife-associated niches, while indicating that the environmental isolate fits within the broader gene content diversity observed in the analyzed dataset.

  • Open Access

    Inhibition of Soluble Epoxide Hydrolase Prevents Docetaxel-Induced Painful Peripheral Neuropathy

    by Karen M. Wagner, Jun Yang, Christophe Morisseau, Bruce D. Hammock

    Chemotherapy-induced peripheral neuropathy (CIPN) is a painful condition recalcitrant to current available therapies. CIPN pain can be severe and dose-limiting or dose-reducing for life-extending chemotherapeutics and, to date, there is no treatment to alter the progression of CIPN. For these experiments we used docetaxel, a first-line therapy for metastatic prostate cancer in humans and investigated the soluble epoxide hydrolase inhibitor EC5026 for its analgesic efficacy against this CIPN pain. Male SD rats (n = 10/group) were pretreated with 1 mg/kg EC5026 in formulated drinking water or vehicle for one week prior to docetaxel injections. The rats continued the formulated drinking water during three once-a-week docetaxel 10 mg/kg i.p. injections and were maintained on treatment until the end of week 5 when all groups were transitioned to normal drinking water. Nociceptive testing occurred throughout the entire experiment including after transitioning to normal drinking water. EC5026 increased mechanical withdrawal thresholds and latencies on the cold plate compared to docetaxel-treated controls. There were no motor effects of the compound, and the formulated drinking water provided favorable exposure. These results demonstrated that EC5026 administered prophylactically was both analgesic and able to limit the severity of mechanical and cold sensitivities in the docetaxel CIPN rat model.


  • Open Access

    Aflatoxin B1 Increases Soluble Epoxide Hydrolase in the Brain and Induces Neuroinflammation and Dopaminergic Neurotoxicity

    by Weicang Wang, Yuxin Wang, Karen M. Wagner, Ruth Diana Lee, Sung Hee Hwang, Christophe Morisseau, Heike Wulff, Bruce D. Hammock

    Parkinson’s disease (PD) is an increasingly common neurodegenerative movement disorder with contributing factors that are still largely unexplored and currently no effective intervention strategy. Epidemiological and pre-clinical studies support the close association between environmental toxicant exposure and PD incidence. Aflatoxin B1 (AFB1), a hazardous mycotoxin commonly present in food and environment, is alarmingly high in many areas of the world. Previous evidence suggests that chronic exposure to AFB1 leads to neurological disorders as well as cancer. However, whether and how aflatoxin B1 contributes to the pathogenesis of PD is poorly understood. Here, oral exposure to AFB1 is shown to induce neuroinflammation, trigger the α-synuclein pathology, and cause dopaminergic neurotoxicity. This was accompanied by the increased expression and enzymatic activity of soluble epoxide hydrolase (sEH) in the mouse brain. Importantly, genetic deletion or pharmacological inhibition of sEH alleviated the AFB1-induced neuroinflammation by reducing microglia activation and suppressing pro-inflammatory factors in the brain. Furthermore, blocking the action of sEH attenuated dopaminergic neuron dysfunction caused by AFB1 in vivo and in vitro. Together, our findings suggest a contributing role of AFB1 to PD etiology and highlight sEH as a potential pharmacological target for alleviating PD-related neuronal disorders caused by AFB1 exposure.


  • Open Access

    Soluble Epoxide Hydrolase Contributes to Cell Senescence and ER Stress in Aging Mice Colon

    by Weicang Wang, Karen M. Wagner, Yuxin Wang, Nalin Singh, Jun Yang, Qiyi He, Christophe Morisseau, Bruce D. Hammock

    Aging, which is characterized by enhanced cell senescence and functional decline of tissues, is a major risk factor for many chronic diseases. Accumulating evidence shows that age-related dysfunction in the colon leads to disorders in multiple organs and systemic inflammation. However, the detailed pathological mechanisms and endogenous regulators underlying colon aging are still largely unknown. Here, we report that the expression and activity of the soluble epoxide hydrolase (sEH) enzyme are increased in the colon of aged mice. Importantly, genetic knockout of sEH attenuated the age-related upregulation of senescent markers p21, p16, Tp53, and β-galactosidase in the colon. Moreover, sEH deficiency alleviated aging-associated endoplasmic reticulum (ER) stress in the colon by reducing both the upstream regulators Perk and Ire1 as well as the downstream pro-apoptotic effectors Chop and Gadd34. Furthermore, treatment with sEH-derived linoleic acid metabolites, dihydroxy-octadecenoic acids (DiHOMEs), decreased cell viability and increased ER stress in human colon CCD-18Co cells in vitro. Together, these results support that the sEH is a key regulator of the aging colon, which highlights its potential application as a therapeutic target for reducing or treating age-related diseases in the colon.


  • Open Access

    Soluble epoxide hydrolase inhibition alleviates chemotherapy induced neuropathic pain

    by Ashley A. Takeshita, Bruce D. Hammock, Karen M. Wagner

    Chemotherapy induced peripheral neuropathy (CIPN) is a particularly pernicious form of neuropathy and the associated pain is the primary dose-limiting factor of life-prolonging chemotherapy treatment. The prevalence of CIPN is high and can last long after treatment has been stopped. Currently, late in the COVID-19 pandemic, there are still increased psychological pressures on cancer patients as well as additional challenges in providing analgesia for them. These include the risks of nonsteroidal anti-inflammatory drug (NSAID) analgesics potentially masking early infection symptoms and the immunosuppression of steroidal and opiate based approaches. Even without these concerns, CIPN is often inadequately treated with few therapies that offer significant pain relief. The experiments we report use soluble epoxide hydrolase inhibitors (sEHI) which relieved this intractable pain in preclinical models. Doses of EC5026, an IND candidate intended to treat neuropathic pain, elicited dose dependent analgesic responses in multiple models including platinum-based, taxane, and vinca alkaloid-based CIPN pain in Sprague Dawley rats. At the same time as a class, the sEHI are known to result in fewer debilitating side effects of other analgesics, likely due to their novel mechanism of action. Overall, the observed dose-dependent analgesia in both male and female rats across multiple models of chemotherapy induced neuropathic pain holds promise as a useful tool when translated to the clinic.


  • Open Access

    Species Differences in Metabolism of Soluble Epoxide Hydrolase Inhibitor, EC1728, Highlight the Importance of Clinically Relevant Screening Mechanisms in Drug Development

    by Cindy B. McReynolds, Jun Yang, Alonso Guedes, Christophe Morisseau, Roberto Garcia, Heather Knych, Caitlin Tearney, Briana Hamamoto, Sung Hee Hwang, Karen Wagner, et al.

    There are few novel therapeutic options available for companion animals, and medications rely heavily on repurposed drugs developed for other species. Considering the diversity of species and breeds in companion animal medicine, comprehensive PK exposures in the companion animal patient is often lacking. The purpose of this paper was to assess the pharmacokinetics after oral and intravenous dosing in domesticated animal species (dogs, cats, and horses) of a novel soluble epoxide hydrolase inhibitor, EC1728, being developed for the treatment of pain in animals. Results: Intravenous and oral administration revealed that bioavailability was similar for dogs, and horses (42 and 50% F) but lower in mice and cats (34 and 8%, respectively). Additionally, clearance was similar between cats and mice, but >2× faster in cats vs. dogs and horses. Efficacy with EC1728 has been demonstrated in mice, dogs, and horses, and despite the rapid clearance of EC1728 in cats, analgesic efficacy was demonstrated in an acute pain model after intravenous but not oral dosing. Conclusion: These results demonstrate that exposures across species can vary, and investigation of therapeutic exposures in target species is needed to provide adequate care that addresses efficacy and avoids toxicity.


  • Top Cited Papers
    Open Access

    Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative

    by Bruce D. Hammock, Cindy B. McReynolds, Karen Wagner, Alan Buckpitt, Irene Cortes-Puch, Glenn Croston, Kin Sing Stephen Lee, Jun Yang, William K. Schmidt, Sung Hee Hwang

    This report describes the development of an orally active analgesic that resolves inflammation and neuropathic pain without the addictive potential of opioids. EC5026 acts on the cytochrome P450 branch of the arachidonate cascade to stabilize epoxides of polyunsaturated fatty acids (EpFA), which are natural mediators that reduce pain, resolve inflammation, and maintain normal blood pressure. EC5026 is a slow-tight binding transition-state mimic that inhibits the soluble epoxide hydrolase (sEH) at picomolar concentrations. The sEH rapidly degrades EpFA; thus, inhibiting sEH increases EpFA in vivo and confers beneficial effects. This mechanism addresses disease states by shifting endoplasmic reticulum stress from promoting cellular senescence and inflammation toward cell survival and homeostasis. We describe the synthesis and optimization of EC5026 and its development through human Phase 1a trials with no drug-related adverse events. Additionally, we outline fundamental work leading to discovery of the analgesic and inflammation-resolving CYP450 branch of the arachidonate cascade.


  • Open Access

    Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive

    by Oscar Sasso, Karen Wagner, Christophe Morisseau, Bora Inceoglu, Bruce D. Hammock, Daniele Piomelli